Latest news with #BDRPharmaceuticals
Time of India
3 days ago
- Health
- Time of India
Gut health is the root cause of unexpected weight gain and cravings
Over the last few years, there has been increasing medical opinion that much of the body's health problems like weight gain and perpetual hunger could be originated in the stomach. For Indians with unexplained weight loss or gain in spite of regular food or measured portions, the solution could lie not in the food they eat but the way the body processes and digests it. The gut, or gastrointestinal tract, is inhabited by trillions of bacteria that comprise what's called the gut microbiome. This intricate community of microorganisms dictates everything from digestion and nutrient consumption to immunity, metabolism, and even mood. If this balance is disrupted a process called dysbiosis it can set off a sequence of metabolic and hormonal reactions that lead to weight gain, bloating, fatigue, and cravings for unhealthy foods. Here's how body weight is affected by gut health: 1. Gut bacteria and metabolism Some species of gut bacteria are responsible for the breakdown of food and its conversion to energy directly. Their imbalance slows down metabolism and leads to fat storage in the body even when calorie consumption is not higher. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Giao dịch CFD với công nghệ và tốc độ tốt hơn IC Markets Đăng ký Undo A non-diverse gut may also release fewer short-chain fatty acids, which are proven to suppress appetite and fat burning. 2. Effect on hunger hormones and cravings An unhealthy gut can elevate levels of ghrelin (the hunger hormone) and lower leptin (the satiety hormone), leaving individuals hungrier more frequently. This imbalance may result in constant cravings, particularly for sugar and processed foods a complaint that most Indian patients with unpredictable eating habits raise. 3. Role of antibiotics and processed foods The overuse of antibiotics, and even consumption of highly processed foods, can destroy the lining of the gut and eliminate beneficial bacteria. Self-medication and frequent use of antibiotics are extremely prevalent in India and lead to chronic digestive imbalances. 4. The stress connection Stress, which is widespread in Indian urban lifestyles, can modify gut microbiota and enhance inflammation. The gut-brain axis two-way communication between the digestive system and the brain — implies that stress has a direct effect on digestion and appetite regulation. How to Enhance Gut Health for Weight Management: - Boost dietary fiber with vegetables, fruits, and whole grain foods. - Eat fermented foods such as curd, buttermilk, idli, and dosa to restore good bacteria. - Don't overuse antibiotics. - Exercise daily and stress manage with yoga or meditation. - Take probiotics under medical supervision. Dr. Aravind Badiger, Technical Director, BDR Pharmaceuticals One step to a healthier you—join Times Health+ Yoga and feel the change
&w=3840&q=100)
Business Standard
09-05-2025
- Health
- Business Standard
Indian hospitals along borders are ready to deal any medical emergencies
During times of war, medical needs go beyond just emergency care. Doctors need to deal with chronic conditions, infectious diseases, mental health issues, and trauma Md Zakariya Khan New Delhi As military tensions mount along India's western frontier following renewed provocations from Pakistan, leading pharmaceutical companies and hospital networks of the country have assured the central government of their readiness to manage any potential medical emergencies. Industry representatives conveyed confidence in their supply chains and emergency response capabilities, underscoring their commitment to national preparedness during uncertain times. 'Critical care products related to hospitals like cephalosporins, painkillers and haemostatic agents… India has enough capacity to meet any eventuality,' Dharmesh Shah, chairman and managing director of Mumbai-based BDR Pharmaceuticals, told Moneycontrol. Shah also said that the government already keeps a stock of these critical care supplies for such situations. The report mentioned that the Fortis Hospital in Amritsar, just 30 kilometres from the Pakistan border, has confirmed it has activated emergency plans after getting an advisory from local authorities. Punjab hospitals gear up for emergencies The hospital has put emergency services on high alert, created a Rapid Response Team, reserved beds for emergencies, and kept its trauma team ready. Fortis also runs hospitals in Ludhiana and Mohali, both located in Punjab, the border state next to Pakistan. Across the state, hospitals have stocked essential medicines, medical supplies, and blood units, while emergency drills are underway to ensure full preparedness. An official from the Indian Pharmaceutical Alliance (IPA) told Moneycontrol that the industry is 'always prepared to support the government with necessary medicines and medical consumables.' Hospitals stock critical supplies, stay prepared Key medicines needed in such situations include painkillers like morphine and paracetamol, antibiotics such as amoxicillin and ciprofloxacin, tetanus injections, IV fluids, and agents to stop bleeding. Hospitals also require supplies like bandages, surgical kits, splints, and equipment for blood transfusions. 'At the moment, the focus of the government is on military objectives, with casualties along the LoC largely being treated by government healthcare facilities,' said Ameera Shah, president of NATHEALTH and executive chairperson of Metropolis Healthcare, as quoted by Moneycontrol. 'In case if there is any escalation of the situation, our members are ready to offer support to the government as we did during the Covid pandemic,' she said.
India.com
05-05-2025
- Health
- India.com
The Gut-Thyroid Connection: How IBS And Hypothyroidism Impact Metabolism
When we think of metabolism, we often picture calorie-burning or energy levels. But beneath that surface lies a far more complex system—one where the gut and the thyroid are in constant conversation. It's becoming increasingly clear that conditions like Irritable Bowel Syndrome (IBS) and hypothyroidism don't just coexist by coincidence—they often feed into each other, creating a ripple effect that can slow down metabolic function, disturb hormonal balance, and leave patients stuck in a loop of chronic symptoms. Dr. Aravind Badiger Technical Director BDR Pharmaceuticals shares the connection between gut and thyroid. The gut is more than just a digestive organ. It plays a role in everything from nutrient absorption to immune regulation—and even hormone activation. In fact, a significant portion of inactive thyroid hormone (T4) is converted into its active form (T3) with the help of the gut microbiome. So, when that microbiome is thrown off balance, as it often is in IBS, thyroid function can be compromised. On the flip side, when thyroid hormones are low, as in hypothyroidism, the entire digestive process slows down. This sluggish gut movement contributes to constipation, bloating, and even bacterial overgrowth—symptoms commonly associated with IBS. It's not just a case of one condition triggering the other; it's a continuous loop. Poor gut health interferes with thyroid hormone conversion and absorption, while hypothyroidism further impairs gut motility and microbial diversity. As a result, patients often experience not just digestive discomfort or fatigue in isolation—but a mix of symptoms that overlap and intensify over time. Adding to this complexity is the role of the immune system. Autoimmune hypothyroidism, such as Hashimoto's, is often linked to increased intestinal permeability—also known as 'leaky gut.' This allows inflammatory molecules and undigested food particles to slip into the bloodstream, potentially triggering or worsening autoimmune responses. What starts in the gut doesn't stay in the gut; it extends its influence to the thyroid, metabolism, mood, and beyond. From a pharmaceutical lens, there's a growing need for integrated solutions. Traditional thyroid hormone replacement therapy, like levothyroxine, remains a mainstay—but in patients with digestive issues, absorption can be inconsistent. This has led to interest in combination therapies that include both T4 and T3, as well as novel formulations that bypass gut absorption altogether. On the gastrointestinal side, treatment approaches are expanding too. Beyond symptom management, targeted therapies now address underlying bacterial imbalances, inflammation, and motility. Medications like rifaximin for SIBO, probiotic support for microbiome restoration, and dietary interventions like the low-FODMAP diet are part of a broader, more interconnected approach to care. The pharmaceutical industry is beginning to respond with research and innovation that respects this complexity, recognizing that when it comes to metabolism, the gut and thyroid are two sides of the same coin. In the end, understanding the gut-thyroid connection is about seeing the body as an integrated whole. It's about moving beyond symptom suppression to systemic support. And as science and medicine continue to catch up with what patients have long felt in their bodies—that everything is connected—we edge closer to real, lasting solutions for both digestive and thyroid health.
Time of India
30-04-2025
- Business
- Time of India
BDR Pharmaceuticals plans $100 mn expansion in the US with manufacturing buyouts
Drugmaker BDR Pharmaceuticals is looking to expand its US footprint through buyouts of manufacturing facilities with an investment of $100 million, its Chairman & Managing Director Dharmesh Shah told ET. The company, which has current revenue of approximately $200 million, is planning to list by 2027, he said. #Pahalgam Terrorist Attack PM Modi-led 'Super Cabinet' reviews J&K security arrangements Pakistan's General Asim Munir is itching for a fight. Are his soldiers willing? India planning to launch military strike against Pakistan within 24 to 36 hours, claims Pak minister 'We are eyeing asset acquisition for manufacturing in the US…We have evaluated a couple of units and we should be deciding on the acquisition in the next three to four months,' said Shah. The planned acquisition will be funded through internal accruals. BDR has a significant portion of its business contributed from value-added CDMO operations focusing on key therapeutic segments such as oncology, critical care, women's healthcare and dermatology. Play Video Pause Skip Backward Skip Forward Unmute Current Time 0:00 / Duration 0:00 Loaded : 0% 0:00 Stream Type LIVE Seek to live, currently behind live LIVE Remaining Time - 0:00 1x Playback Rate Chapters Chapters Descriptions descriptions off , selected Captions captions settings , opens captions settings dialog captions off , selected Audio Track default , selected Picture-in-Picture Fullscreen This is a modal window. Beginning of dialog window. Escape will cancel and close the window. Text Color White Black Red Green Blue Yellow Magenta Cyan Opacity Opaque Semi-Transparent Text Background Color Black White Red Green Blue Yellow Magenta Cyan Opacity Opaque Semi-Transparent Transparent Caption Area Background Color Black White Red Green Blue Yellow Magenta Cyan Opacity Transparent Semi-Transparent Opaque Font Size 50% 75% 100% 125% 150% 175% 200% 300% 400% Text Edge Style None Raised Depressed Uniform Drop shadow Font Family Proportional Sans-Serif Monospace Sans-Serif Proportional Serif Monospace Serif Casual Script Small Caps Reset restore all settings to the default values Done Close Modal Dialog End of dialog window. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Google Brain Co-Founder Breaks His Silence: Read These 5 Books And Turn Your Life Around Blinkist: Andrew Ng's Reading List Undo Industry experts said the uncertainty surrounding the US tariffs may prompt many Indian manufacturers to acquire assets in the US that will enable them to avoid significant cost increase they would otherwise incur on exporting the finished drug. 'We want to manufacture in the US certain controlled substances and complex molecules. The reason being that the US, if you have to cater to the defense sector, the preference is for the local producer,' said Shah. 'We prefer that we have an establishment there and we do the tech transfer and manufacture there and cater locally to the government.' Live Events Shah added that the company has been planning this expansion over the last one year. 'Our thought process has been there for last one year. US is a big market and local defense buying is also huge. It's always better to produce locally,' he added. 'Inorganic definitely helps you to fast track approval,' said Shah. BDR, which has tie-ups with top Indian pharma companies like Dr Reddy's, Sun Pharma , Cipla , Zydus , and Torrent, is evaluating 200 ANDAs in the US. These include solid dosage and injectables in cardiology, diabetology, pain management, dermatology and HIV. 'Around 45% or 80-90 of these ANDAs are going to be commercialised,' said Shah. On the impact of possible tariffs on exports of pharmaceutical products from India, Shah said, 'The current geopolitical situations are very uncertain due to a lot of things happening. But the operating cost in the US is very high and the dependence on active raw material is largely on India and China - which is the major cost contributing factor. That's where, with India being a preferred partner, Indian generics don't need to worry about.' India is a major supplier of generic medicines to the US market. Its exports worth about $9 billion in value terms account for 40% of the medicines consumed in the US. 'Because there's a huge difference in operating cost as well as the backward integration strength. I don't believe it is in the interest of even the US to make generics expensive.' The company, which is now globally into oncology molecule, is also in the process of setting up a new plant for complex oncological injectable at Halol near Vadodara in Gujarat, where it already has two facilities for complex injectable and oral solid dosage in areas such as anti-inflammatory, antibiotics and others. The company has already started the process for FDA approval and almost seven filings for complex oncology molecules are lined up this year. The company is filing for approval for a new drug delivery system in oncology, for geriatric patients, under 505B2 which is a streamlined FDA drug approval process that allows use of existing data.
